GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intravenous Infusions Ltd (XGHA:IIL) » Definitions » 3-Year EBITDA Growth Rate

Intravenous Infusions (XGHA:IIL) 3-Year EBITDA Growth Rate : 0.00% (As of . 20)


View and export this data going back to 2015. Start your Free Trial

What is Intravenous Infusions 3-Year EBITDA Growth Rate?

Intravenous Infusions's EBITDA per Share for the six months ended in . 20 was GHS0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Intravenous Infusions's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intravenous Infusions's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Intravenous Infusions's 3-Year EBITDA Growth Rate falls into.



Intravenous Infusions 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Intravenous Infusions  (XGHA:IIL) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Intravenous Infusions 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Intravenous Infusions's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Intravenous Infusions (XGHA:IIL) Business Description

Traded in Other Exchanges
N/A
Address
Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.